Our Company

THE LEADING RNAi THERAPEUTICS COMPANY

Alnylam has led the translation of RNA interference (RNAi) from Nobel Prize-winning discovery into an entirely new class of medicines, which we believe has the potential to help people all over the world to live longer, healthier, and fuller lives. Through pioneering science, unwavering commitment to patients, and our approved therapies and deep pipeline of investigational RNAi therapeutics, we have cemented our reputation for innovation and leadership in RNAi.

LEARN MORE ›

OUR SCIENCE IS CHANGING THE WAY
MEDICINE TREATS DISEASE

Video Image

Video Image mobile-video

Our Science

OUR PIPELINE

Our robust pipeline of investigational RNAi therapeutics is focused on diseases with high unmet medical need which fall into four main therapeutic areas: genetic medicines, cardio-metabolic diseases, infectious diseases, and central nervous system (CNS) and ocular diseases. We have more than a dozen RNAi therapeutics in clinical development, including multiple in late-stage development.

 

Genetic Medicines

 

Cardio-Metabolic Diseases

 

Infectious Diseases

 

Central Nervous System & Ocular Diseases

EXPLORE OUR PIPELINE ›

PATIENTS COME FIRST

Whether we're working to develop the first treatment for a disease or a better one, patients are the center of all we do. They are the reason we come to work every day, and their stories inspire us to continue to innovate by pushing the science of RNAi therapeutics forward.

My body started to warn me that something was wrong. That I had a problem… My father passed away 40 years ago; after I received my diagnosis, we believe what he really had was hATTR amyloidosis like me.

-Chen, living with hATTR amyloidosis

 
Our News

ALNYLAM NEWS

FDA Approves AMVUTTRA™ (vutrisiran) for Patients in the U.S.
Approval represents our 5th approved medicine
view article ›
Alnylam Publishes 2021 Annual Report
Alnylam Publishes 2021 Annual Report
Our annual look back, and forward to what’s next in the RNAi Revolution
view article ›
Corporate Responsibility at Alnylam
Corporate Responsibility at Alnylam
We’ve published our second annual Corporate Responsibility Report
view article ›
Celebrating 20 Years of Alnylam Leadership
And what’s next in the RNAi Revolution.
view article ›
FDA approves Leqvio
FDA approves Leqvio® (inclisiran)
Approval is first in U.S. for an RNAi medicine in a highly prevalent disease
view article ›
Corporate Responsibility

 

Corporate Responsibility

We accept bold challenges to improve the health of humanity. 
We believe that our actions as a company and employees can be a force for good in the world. Consistent with our core values, we are relentless advocates for science, patients, employees, communities, and our planet.

LEARN MORE ›

Our Company

Diversity, Equity & Inclusion 

We are proud of the award-winning, open, dynamic, and diverse culture we have built, where employees feel included, supported, and heard. We are committed to building a work environment with a shared mission and values, where all employees feel they belong and are enabled to achieve their full potential.

READ MORE ›

homepage4
Job Seekers
Job Seekers

This is your moment to join us

We're 1,800+ smart, passionate, "change the world" kind of people who believe deeply in the power and potential of our technology and what we're building as a company. If you are looking for a mission and colleagues that inspire and a company that recognizes and rewards both group and individual contributions, perhaps this is your moment to join us.

JOIN US ›